(CercleFinance.com) – Eurobio Scientific announces that it has signed an agreement today to acquire 100% of the capital and voting rights of the Dutch company Genome Diagnostics BV (GenDx) for an amount of 135 million euros.
This acquisition will allow Eurobio Scientific to complete its commercial portfolio with a range of 100% proprietary products among the most efficient in the field of HLA (human leukocyte antigen) diagnosis in order to assess the compatibility between donors and recipients in the context of transplants. organs and marrow.
It will also allow it to strengthen its geographical footprint, mainly in Europe and the USA.
‘The strong complementarity between our two companies should make it possible to increase our Group’s lead technologically, geographically and commercially’, summarizes Denis Fortier, Deputy Managing Director and co-CEO of Eurobio Scientific.